title: Hepatitis C--who should be treated?
authors.forename: Gary S
authors.initials: GS
authors.lastname: Wolfe
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D019090:Case Management / Q000458:organization & administration*; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D024802:Nurse's Role; D018579:Patient Selection; D011322:Primary Prevention / Q000379:methods; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D000637:Transaminases